Interview: Ernest Bartosik, Country Manager, Unipharm, Poland
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Unipharm is an American pharmaceutical company specializing in the development and marketing of quality over-the-counter (OTC) drugs and nutritional products. Since it was established in the USA in 1992, the Company has consistently grown, and continues to provide award-winning, quality products to its loyal customers in many different countries.
Unipharm has been for many years registered with the US Food and Drug Administration. All of Unipharm’s products are made in the USA under extensive quality control supervision at well-established facilities that follow Good Manufacturing Practice (GMP) guidelines and United States Pharmacopeia (USP) standards. We are also proud to be certified by National Sanitation Foundation (NSF) International. In addition, our products are manufactured, tested and packaged according to regulations mandated by every country the Company sells in.
The world headquarters of Unipharm is located here in the Empire State Building in New York City, and there are many branch offices worldwide. Unipharm products are successful, both in terms of brand awareness and sales, and this is demonstrated by the kind of loyalty that you, our loyal customers, demonstrate to us. The Company is committed to continue offering a wide variety of quality goods that are both safe and effective.
In Poland Unipharm’s offer is dedicated to physicians, their patients, and consumers in area of joint care, bone health, osteoporosis, beauty, aging, memory loss and immune support. The Company is deeply engaged in both health education and activities which support healthy life, medical prophylaxis and treatment.
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the…
Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he…
Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging…
Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to…
Michael Dembinski, chief advisor of the British Polish Chamber of Commerce, discusses the important role of the chamber in driving forward Polish clinical trials and the challenges in unlocking Poland’s…
Mirosław Wysocki, national consultant in the area of Public Health, professor at the National Institute of Public Health (NIH), the research institute responsible inter alia for health promotion and disease…
Monika Constant, director general of the French-Polish Chamber of Commerce in Poland (CCIFP), discusses the evolution of the two nations’ bilateral business relationship, the benefits of conducting business in Poland,…
Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care…
Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research…
Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims…
Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction…
Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to…
See our Cookie Privacy Policy Here